Stereoisomer and deuterated derivative of pyrazoloquinazoline compound and use

MYPI2025004210A0Undetermined Publication Date: 2024-07-17PHIL RIVERS TECH LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025004210
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-20
Filing Date
2024-01-17
Publication Date
2024-07-17

AI Technical Summary

Technical Problem

Existing PLK1 inhibitors have failed to achieve satisfactory therapeutic effects in clinical applications due to dose-limiting toxicity issues, and their absorption and bioavailability vary greatly in different species, leading to development challenges.

Method used

Stereoisomers and deuterated derivatives of pyrazoloquinolines were developed. Through stereocyclization modification and deuterium addition, the oral absorption and bioavailability of these compounds were improved, and the toxicity was reduced.

Benefits of technology

As effective PLK1 inhibitors, these compounds significantly improve the therapeutic effect on various cancer types, provide a richer range of drug efficacy options, and reduce toxicity, and are suitable for the treatment of diseases including leukemia, lymphoma, pancreatic cancer, etc.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025004210_DRAWING_001
    Figure PI2025004210_DRAWING_001
  • Figure PI2025004210_DRAWING_002
    Figure PI2025004210_DRAWING_002
  • Figure PI2025004210_DRAWING_003
    Figure PI2025004210_DRAWING_003
Patent Text Reader

Abstract

The present disclosure provides a stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of a compound represented by formula (I), or a pharmaceutically acceptable salt and solvate thereof, which can be used as a PLK1 inhibitor, wherein R1 and R2 are as described herein. Further provided are a pharmaceutical composition comprising the stereoisomer, deuterated derivative or stereoisomeric deuterated derivative, or the pharmaceutically acceptable salt and solvate, and a use in the treatment of diseases and symptoms caused by PLK1 activity disorders and / or PLK1-related diseases and symptoms, such as cancer. (I) Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

Stereoisomers and deuterated derivatives of pyrazoloquinazoline compounds and their applications

[0001] This application claims priority to Chinese Patent Application No. 202310083163.X filed on January 17, 2023 and Chinese Patent Application No. 202310430237.2 filed on April 20, 2023, the entireties of which are hereby incorporated by reference. Technical Field

[0002] The present disclosure relates to stereoisomers, deuterated derivatives, or stereoisomeric deuterated derivatives of pyrazoloquinoline compounds, or pharmaceutically acceptable salts or solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising one or more such stereoisomers and derivatives, or pharmaceutically acceptable salts or solvates thereof, as active ingredients. The present disclosure also relates to such stereoisomers and derivatives, or pharmaceutically acceptable salts or solvates thereof, and the use of such stereoisomeric derivatives, or pharmaceutically acceptable salts or solvates thereof, as polo-like kinase inhibitors. Background Art

[0003] The mammalian polo-like kinases (PLKs) are composed of five families of serine / threonine kinases (PLKs1-5) with distinct functions and expression patterns in mammalian cells. Most PLKs possess a C-terminal polo-box domain (PBD) that recognizes substrates and an N-terminal kinase domain that phosphorylates them. Among PLKs, PLK1 is the most extensively studied family member and has key functions in cell cycle progression, particularly in the G2-M checkpoint, mitosis, and cytokinesis. PLK1 activity is tightly regulated during cell cycle progression through its association with other phosphorylation scaffold proteins.

[0004] PLK1 has been extensively studied as an attractive target for cancer therapy, and several small-molecule PLK1 inhibitors have been developed over the past decade. These inhibitors target both liquid tumors such as leukemia and lymphoma, as well as solid tumors such as pancreatic, breast, and prostate cancers. However, despite demonstrating antitumor effects in preclinical cancer models and initial promising results in clinical trials, PLK1 inhibitors have yet to achieve satisfactory therapeutic efficacy due to dose-limiting toxicity (Translational Oncology Volume 16, February 2022, 101-332). ATP-competitive inhibitors targeting PLK1 are currently under clinical development, with onvansertib (NMS-P937, NMS1286937) showing high selectivity and promising clinical development prospects. However, among the onvansertib derivatives (Bioorg Med Chem Lett. 2011 May 15; 21(10): 2969-74, Bioorg Med Chem Lett. 2010 Nov 15; 20(22): 6489-94), most derivative molecules have very poor oral absorption and bioavailability in mice. The literature (Mol Cancer Ther; 11(4) April 2012, Supplementary table S4) also disclosed that the absorption and bioavailability of the same onvansertib in different species vary greatly and are irregular, posing a challenge to the development of selective PLK1 inhibitors.

[0005] The project team members of this study unexpectedly discovered that by stereocyclization modification, deuteration, and stereocyclization plus deuteration at the N-methylpiperazine of onvansertib, its oral absorption, bioavailability, tissue distribution and other parameters can be well regulated. In multiple animal experiments, it can be seen that the modified molecules have lower toxicity and better efficacy than onvansertib, providing a richer selection of effective molecules for different types of diseases.

[0006] Summary of the Invention

[0007] Disclosed herein are stereoisomers, deuterated derivatives, or stereoisomeric deuterated derivatives of pyrazoloquinoline compounds as polo-like kinase inhibitors, or pharmaceutically acceptable salts or solvates thereof. Therefore, the compounds disclosed herein are particularly suitable for targeting PLK1 and for treating diseases and conditions caused by dysregulated PLK1 activity and / or diseases and conditions associated with PLK1, including but not limited to leukemia, lymphoma, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, colorectal cancer, liver cancer, gastric cancer, esophageal cancer, melanoma, multiple myeloma, and sepsis.

[0008] In one aspect, the present disclosure relates to stereoisomers, deuterated derivatives, or stereoisomeric deuterated derivatives of compounds of formula (I):

[0009] or a pharmaceutically acceptable salt or solvate thereof,

[0010] Among them, R 1 and R 2 are each independently selected from hydrogen, deuterium, deuterated or undeuterated C 1-6 Alkyl; or R 1 and R 2 Together with the N atom and the C atom to which it is connected, it forms a 5-membered heterocyclic ring;

[0011] Optionally and / or

[0012] Optionally substituted with one or more deuteriums.

[0013] In another aspect, the present disclosure relates to a pharmaceutical composition comprising a stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of a compound of formula (I) as provided herein, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or excipient.

[0014] In another aspect, the present disclosure relates to a method for treating diseases and conditions caused by dysregulated PLK1 activity and / or diseases and conditions associated with PLK1 in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a stereoisomer, deuterated derivative, or stereoisomeric deuterated derivative of a compound of formula (I) as provided herein, or a pharmaceutically acceptable salt or solvate thereof.

[0015] In another aspect, the present disclosure relates to stereoisomers, deuterated derivatives or stereoisomeric deuterated derivatives of compounds of formula (I) as provided herein, or pharmaceutically acceptable salts or solvates thereof for use in treating diseases and conditions caused by dysregulation of PLK1 activity and / or diseases and conditions associated with PLK1.

[0016] In another aspect, the present disclosure relates to the use of stereoisomers, deuterated derivatives or stereoisomeric deuterated derivatives of the compound of formula (I) as provided herein, or pharmaceutically acceptable salts or solvates thereof, in the preparation of medicaments for treating diseases and conditions caused by dysregulation of PLK1 activity and / or diseases and conditions associated with PLK1.

[0017] In another aspect, the present disclosure relates to a kit for treating diseases and conditions caused by dysregulated PLK1 activity and / or diseases and conditions associated with PLK1, the kit comprising: a stereoisomer, deuterated derivative, or stereoisomeric deuterated derivative of a compound of formula (I) as provided herein, or a pharmaceutically acceptable salt, solvate thereof, or a pharmaceutical composition comprising a stereoisomer, deuterated derivative, or stereoisomeric deuterated derivative of a compound of formula (I) as provided herein, or a pharmaceutically acceptable salt, solvate thereof and a pharmaceutically acceptable carrier or excipient, a container, and optionally a package insert or label indicating treatment.

[0018] Diseases and conditions caused by dysregulated PLK1 activity and / or diseases and conditions associated with PLK1 include, but are not limited to, leukemia, lymphoma, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, colorectal cancer, liver cancer, gastric cancer, esophageal cancer, melanoma, multiple myeloma, and sepsis. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] FIG1 shows the IC values ​​of the inhibitory effects of the disclosed example compounds and Yangshen compounds on pancreatic cancer cell line (PSN1) 50 Among them, A is CPD02 of the present disclosure; B is CPD03 of the present disclosure; C is Yangshen compound NMS-P937; D is CPD04 of the present disclosure; and is CPD06 of the present disclosure.

[0020] FIG2 shows a graph showing the tumor growth curve of the HCT116 subcutaneous xenograft mouse model after the start of treatment with the disclosed compounds.

[0021] FIG3 shows the body weight change curve of experimental animals in the HCT116 subcutaneous transplanted tumor mouse model after the start of treatment with the disclosed compounds.

[0022] FIG4 shows a graph showing the tumor growth curve of the BxPC-3 subcutaneous xenograft mouse model after the start of treatment with the disclosed compounds.

[0023] FIG5 shows the body weight change curve of experimental animals in the BxPC-3 subcutaneous transplanted tumor mouse model after the start of treatment with the disclosed compounds.

[0024] FIG6 shows a graph showing the tumor growth curve of a PSN1 subcutaneous xenograft mouse model after the start of treatment with the disclosed compounds.

[0025] FIG7 shows the body weight change curve of experimental animals in the PSN1 subcutaneous transplanted tumor mouse model after the start of treatment with the disclosed compounds. DETAILED DESCRIPTION

[0026] Certain embodiments will now be described in detail, examples of which are illustrated in the accompanying specific embodiments. Although the embodiments listed will be described, it should be understood that they are not intended to limit the present disclosure to these embodiments. On the contrary, the present disclosure is intended to cover all alternatives, modifications and equivalents, which may be included within the scope of the present disclosure as defined by the claims. Those skilled in the art will recognize that many methods and materials similar or equivalent to the methods and materials described herein can be used in the practice of the present disclosure. The present disclosure is in no way limited to the methods and materials described. If one or more incorporated documents and similar materials differ from or contradict the present disclosure, including but not limited to defined terms, term usage, described technology, etc., the present disclosure shall prevail.

[0027] It will be understood that certain features of the disclosure, which are, for clarity, described in the context of separate embodiments, may also be provided combined in a single embodiment. Conversely, for brevity, various features of the disclosure that are described in the context of a single implementation may also be provided separately or in any suitable subcombination.

[0028] This article provides the following content.

[0029] Item 1. A stereoisomer, deuterated derivative, or stereoisomeric deuterated derivative of a compound of formula (I):

[0030] or a pharmaceutically acceptable salt or solvate thereof,

[0031] Among them, R 1 and R 2 are each independently selected from hydrogen, deuterium, deuterated or undeuterated C 1-6 Alkyl; or R 1 and R 2 Together with the N atom and the C atom to which it is attached, it forms an optionally substituted deuterated or undeuterated 5-membered heterocyclic ring;

[0032] Optionally and / or

[0033] Optionally substituted with one or more deuteriums.

[0034] Item 2. A stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of a compound of formula (I) according to Item 1, or a pharmaceutically acceptable salt or solvate thereof, wherein

[0035] R 1 Is deuterated or undeuterated C 1-6 Alkyl, preferably methyl or deuterated methyl, more preferably perdeuterated methyl;

[0036] R 2It is hydrogen or deuterium.

[0037] Item 3. A stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of a compound of formula (I) according to Item 1, or a pharmaceutically acceptable salt or solvate thereof, wherein

[0038] R 1 and R 2 Together with the N atom and the C atom to which it is connected, it forms an optionally substituted 5-membered heterocyclic ring as described below:

[0039] wherein the 5-membered heterocyclic ring is optionally substituted by 1-7 deuterium groups.

[0040] Item 4. A stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of a compound of formula (I) according to Item 3, or a pharmaceutically acceptable salt or solvate thereof, wherein

[0041] R 1 and R 2 Together with the N atom and the C atom to which it is connected, it forms an optionally substituted 5-membered heterocyclic ring selected from the following:

[0042] wherein the 5-membered heterocyclic ring is optionally substituted by 1-7 deuterium groups.

[0043] Item 5. A stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of the compound (I) according to any one of the preceding items, or a pharmaceutically acceptable salt or solvate thereof, wherein

[0044] Optionally substituted with 1-8 deuteriums.

[0045] Item 6. A stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of the compound of formula (I) according to Item 1, or a pharmaceutically acceptable salt or solvate thereof, wherein the stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of the compound of formula (I) is selected from the following:

[0046] Item 7. A pharmaceutical composition comprising a stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of a compound of formula (I) according to any one of Items 1 to 6, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or excipient.

[0047] Item 8. A method for treating diseases and conditions caused by dysregulated PLK1 activity and / or diseases and conditions associated with PLK1 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of a compound of formula (I) according to any one of Items 1 to 6, or a pharmaceutically acceptable salt or solvate thereof.

[0048] Item 9. The method according to Item 8, wherein the diseases and conditions caused by dysregulated PLK1 activity and / or the diseases and conditions associated with PLK1 are selected from the group consisting of: leukemia, lymphoma, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, colorectal cancer, liver cancer, gastric cancer, esophageal cancer, melanoma, multiple myeloma, and sepsis.

[0049] Item 10. A stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of a compound of formula (I) according to any one of Items 1 to 6, or a pharmaceutically acceptable salt or solvate thereof, for use in treating diseases and conditions caused by dysregulation of PLK1 activity and / or diseases and conditions associated with PLK1.

[0050] Item 11. A stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of the compound of formula (I) for use in treating diseases and conditions caused by dysregulation of PLK1 activity and / or diseases and conditions related to PLK1 according to Item 10, or a pharmaceutically acceptable salt or solvate thereof, wherein the diseases and conditions caused by dysregulation of PLK1 activity and / or diseases and conditions related to PLK1 are selected from the group consisting of leukemia, lymphoma, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, colorectal cancer, liver cancer, gastric cancer, esophageal cancer, melanoma, multiple myeloma, and sepsis.

[0051] Item 12. Use of a stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of a compound of formula (I) according to any one of Items 1 to 6, or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament for treating diseases and conditions caused by dysregulation of PLK1 activity and / or diseases and conditions associated with PLK1.

[0052] Item 13. The use according to Item 12, wherein the diseases and conditions caused by dysregulated PLK1 activity and / or the diseases and conditions associated with PLK1 are selected from the group consisting of: leukemia, lymphoma, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, colorectal cancer, liver cancer, gastric cancer, esophageal cancer, melanoma, multiple myeloma, and sepsis.

[0053] Item 14. A kit for treating diseases and conditions caused by dysregulated PLK1 activity and / or diseases and conditions associated with PLK1, the kit comprising

[0054] A stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of a compound of formula (I) according to any one of items 1 to 6, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition according to item 7;

[0055] Container; and

[0056] Optional package insert or label indicating treatment.

[0057] Item 15. The kit according to Item 14, wherein the diseases and conditions caused by dysregulated PLK1 activity and / or the diseases and conditions associated with PLK1 are selected from the group consisting of: leukemia, lymphoma, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, colorectal cancer, liver cancer, gastric cancer, esophageal cancer, melanoma, multiple myeloma, and sepsis.

[0058] definition

[0059] Terms used but not defined herein have their ordinary meanings, and the meanings of such terms are independent at each occurrence thereof. However, unless otherwise indicated, the following definitions apply throughout the specification and claims.

[0060] As used herein, the terms “comprising” and “including” are intended to specify the presence of stated features, integers, components or steps, but they do not preclude the presence or addition of one or more other features, integers, components, steps or groups thereof.

[0061] The definitions of specific functional groups and chemical terms are described in more detail below. For the purposes of this disclosure, chemical elements are identified according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th edition, inside cover, and specific functional groups are generally defined as described therein. In addition, the general principles of organic chemistry as well as specific functional moieties and reactivity are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito, 1999; Smith and March, March's Advanced Organic Chemistry, 5th edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; Carruthers, Some Modem Methods of Organic Synthesis, 3rd edition, Cambridge University Press, Cambridge, 1987.

[0062] All ranges cited herein are inclusive unless expressly stated otherwise.

[0063] When a range of values ​​is listed, it is intended that every value and subrange within that range be included. For example, “C 1-6 "Aims to cover C1, C2, C3, C4, C5, C6, C 1-6 、C 1-5 、C 1-4 、C 1-3 、C 1-2 、C 2-6 、C 2-5 、C 2-4 、C 2-3 、C 3-6 、C 3-5 、C 3-4 、C 4-6 、C 4-5 and C 5-6 .

[0064] When any variable occurs more than one time in any constituent or in Formula (I) or in any other formula depicting and describing compounds of the present disclosure, its definition on each occurrence is independent of its definition at every other occurrence. Furthermore, combinations of substituents and / or variables are permissible only if such combinations result in stable compounds.

[0065] As used herein, the term "deuterated" refers to a compound or group in which one or more hydrogen atoms are replaced by deuterium. When a compound or group is deuterated, one, two, three, or even more hydrogen atoms on the compound or group may be replaced by deuterium, until all hydrogen atoms on the compound or group are replaced by deuterium. In this case, the compound or group is referred to as a "perdeuterated compound or group."

[0066] In some embodiments, at deuterated positions, the deuterium isotope abundance is greater than the natural deuterium isotope abundance (0.015%), preferably greater than 50%, more preferably greater than 60%, greater than 70%, greater than 80%, greater than 90%, greater than 95%, greater than 96%, greater than 97%, greater than 98%, greater than 99%, greater than 99.5%, or 100%.

[0067] In some cases, such as when "hydrogen" and "deuterium" appear in a statement as parallel alternatives or when "hydrogen" is replaced by "deuterium", the term "hydrogen" refers to the hydrogen isotope " 1 hydrogen( 1 H)", while the term "deuterium" refers to the hydrogen isotope " 2 hydrogen( 2H)"; or it is understood that at that position of the compound, hydrogen in a state where its various isotopic abundances are naturally present is replaced by deuterium in a state where deuterium is present at a greater abundance than the natural deuterium isotopic abundance (e.g., a deuterium abundance of greater than 50%, greater than 60%, greater than 70%, greater than 80%, greater than 90%, greater than 95%, greater than 96%, greater than 97%, greater than 98%, greater than 99%, greater than 99.5%, or 100%).

[0068] In some embodiments, When optionally substituted with a deuterium, the deuterium may be substituted on any ring carbon atom. In some embodiments, When optionally substituted with two or more deuteriums, these two or more deuteriums may be substituted on the same ring carbon atom or on different ring carbon atoms.

[0069] In some embodiments, when R 2 When it is hydrogen, for At this time, including R 2 The hydrogen atoms on the ring carbon atoms may be replaced by 1 to 8 deuterium atoms, for example 1, 2, 3, 4, 5, 6, 7 or 8 deuterium atoms. These deuterium atoms may be substituted on the same or different ring carbon atoms.

[0070] In some embodiments, when R 1 is an undeuterated methyl group and R 2 When it is hydrogen, for At this time, including R 2 At least one hydrogen on a ring carbon atom within the ring is replaced by deuterium, for example, by 1, 2, 3, 4, 5, 6, 7 or 8 deuterium substitutions. These deuterium substitutions can be on the same or different ring carbon atoms.

[0071] In a preferred embodiment, the optionally deuterated Selected from R 1 Optionally undeuterated, such as undeuterated methyl, or deuterated, such as perdeuterated methyl, e.g.

[0072] In some embodiments, when for or its stereoisomers When two or more deuterium groups are present, one or more deuterium groups may be substituted on any ring carbon atom; when two or more deuterium groups are present, these two or more deuterium groups may be substituted on the same ring carbon atom or on different ring carbon atoms. In some embodiments, when two or more deuterium groups are present, these two or more deuterium groups may be substituted on one ring in a fused ring structure or on both rings in a fused ring structure. In some embodiments, one or more deuterium groups may be substituted on a carbon atom shared by both rings in a fused ring structure.

[0073] In a preferred embodiment, the optionally deuterated Selected from

[0074] In some embodiments, when is not substituted by deuterium hour, yes

[0075] As used herein, the term "alkyl" refers to a straight or branched chain saturated hydrocarbon group. i-j "Alkyl" refers to an alkyl group having i to j carbon atoms. Unless otherwise specified, an alkyl group can contain 1 to 10 carbon atoms. In certain embodiments, the alkyl group contains 1 to 6 carbon atoms, e.g., 1 to 5 carbon atoms, 1 to 4 carbon atoms, 1 to 3 carbon atoms, or 1 to 2 carbon atoms. Non-limiting examples of alkyl groups include methyl, ethyl, n- and isopropyl, n-, sec-, iso- and tert-butyl, neopentyl, and the like.

[0076] As used herein, the term "deuterated alkyl" is a substituent obtained by replacing one or more hydrogen atoms on an alkyl group with deuterium. When an alkyl group is deuterated, one, two, three, or even more hydrogen atoms on the alkyl group may be replaced by deuterium, until all hydrogen atoms on the alkyl group are replaced by deuterium, in which case it may be referred to as a "perdeuterated alkyl group." In some embodiments, non-limiting examples of deuterated alkyl groups include deuterated methyl groups, such as monodeuterated methyl groups, dideuterated methyl groups, trideuterated methyl groups (perdeuterated methyl groups), monodeuterated ethyl groups, dideuterated ethyl groups, trideuterated ethyl groups, tetradeuterated ethyl groups, pentadeuterated ethyl groups (perdeuterated ethyl groups), and the like.

[0077] As used herein, the term "cycloalkyl" refers to non-aromatic, saturated monocyclic and polycyclic ring systems in which all ring atoms are carbon. Unless otherwise specified, a cycloalkyl group may contain 3 to 10 ring carbon atoms (i.e., C 3-10Cycloalkyl). In certain embodiments, the cycloalkyl group can contain 3 to 9, 3 to 8, 3 to 7, 3 to 6, 4 to 10, 4 to 9, 4 to 8, 4 to 7, 4 to 6, 4 to 5, 5 to 10, 5 to 9, 5 to 8, 5 to 7, 5 to 6 ring-forming carbon atoms, etc. In particular, the cycloalkyl can be monocyclic or bicyclic. Alternatively, the bicyclic cycloalkyl group can include fused, spirocyclic and bridged cycloalkyl structures.

[0078] On the other hand, also include the cycloalkyl ring that wherein 1,2 or 3 heteroatoms replace into ring carbon atom.This type of group is referred to as " heterocyclic radical " or " heterocycle ", and it refers to as defined above but with at least one heteroatom selected from N, O and S as the cycloalkyl group of ring-forming atoms.Unless otherwise indicated, heterocyclic radical group can contain 3 to 10 ring-forming atoms (i.e. 3 to 10 yuan of heterocyclic radicals).In certain embodiments, heterocyclic radical group can contain 3 to 9,3 to 8,3 to 7,3 to 6,4 to 10,4 to 9,4 to 8,4 to 7,4 to 6,4 to 5,5 to 10,5 to 9,5 to 8,5 to 7,5 to 6 ring-forming atoms etc.Especially, heterocyclic radical group can be monocycle or bicyclic.Alternatively, bicyclic heterocyclic radical group can include condensation, spirocycle and bridged heterocyclic radical structure. Non-limiting examples of heterocyclyl groups include oxiranyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl, piperazinyl, pyrrolidinyl, and morpholinyl. Heterocyclyl groups can also be described by using the number of carbon atoms. For example, C 3-6 Heterocyclyl refers to a heterocyclyl group containing three to six ring-forming carbon atoms, and can also contain at least one heteroatom, such as 1, 2 or 3 heteroatoms as ring-forming atoms. In certain embodiments, the heterocyclyl group or heterocycle contains 1 or 2 heteroatoms as ring-forming atoms. In certain embodiments, the heterocyclyl group can be monocyclic or bicyclic, such as fused bicyclic and spiro bicyclic. In the context of the present disclosure, the terms "heterocyclyl" and "heterocycle" can be used interchangeably.

[0079] As used herein, the term "deuterated heterocyclyl" refers to a substituent in which one or more hydrogen atoms on a heterocyclyl group are replaced with deuterium. When a heterocyclyl group is deuterated, one, two, three, or even more hydrogen atoms on the heterocyclyl group may be replaced with deuterium, until all hydrogen atoms on the heterocyclyl group are replaced with deuterium. In this case, the heterocyclyl group is referred to as a "perdeuterated heterocyclyl."

[0080] As used herein, the term "halo" or "halogen" refers to fluoride, chloride, bromide and iodide. In certain embodiments, non-limiting examples of halo include fluoride, chloride and bromide, more particularly fluoride and chloride.

[0081] As used herein, the term "heteroatom" refers to nitrogen (N), oxygen (O), and sulfur (S), and can include any oxidized forms of nitrogen and sulfur, and any quaternized forms of basic nitrogen, unless otherwise specified.

[0082] As used herein, the term "substituted" when referring to a chemical group means that the chemical group has one or more hydrogen atoms that are removed and replaced by a substituent. As used herein, the term "substituent" has its ordinary meaning as known in the art and refers to a chemical moiety that is covalently attached to a parent group or, if appropriate, fused to a parent group. It will be understood that substitution of a given atom is limited by valence. It will be understood that a substituent may be further substituted.

[0083] When it is stated in Formula (I) or any embodiment thereof that a moiety is "optionally" substituted, this means that Formula (I) or its embodiments encompasses compounds that are substituted with the indicated substituents on that moiety and compounds that do not contain the indicated substituents on that moiety (i.e., wherein the moiety is unsubstituted).

[0084] The compounds provided herein are described with reference to general formulae and specific compounds. In addition, the compounds of the present disclosure may exist in a variety of different forms or derivatives, all of which are within the scope of the present disclosure. These include, for example, pharmaceutically acceptable salts, tautomers, stereoisomers, racemic mixtures, positional isomers, prodrugs, solvated forms, different crystalline forms or polymorphs, and active metabolites.

[0085] As used herein, unless otherwise indicated, the term "pharmaceutically acceptable salt" includes salts that maintain the biological effectiveness of the free acid / alkaline form of a particular compound and are not undesirable biologically or otherwise. Pharmaceutically acceptable salts can include salts formed with inorganic bases or acids and organic bases or acids. In the case where the compounds of the present disclosure contain one or more acidic or basic groups, the disclosure also includes their corresponding pharmaceutically acceptable salts. Therefore, compounds of the present disclosure containing acidic groups (such as carboxyl groups) can exist in salt form and can be used according to the disclosure, for example, alkali metal salts, alkaline earth metal salts, aluminum salts or ammonium salts. More non-limiting examples of such salts include lithium salts, sodium salts, potassium salts, calcium salts, magnesium salts, barium salts or salts with ammonia or organic amines (such as ethylamine, ethanolamine, diethanolamine, triethanolamine, piperidine, N-methylglutamine or amino acids). For example, by reacting a compound with an acidic group with a suitable base (e.g., lithium hydroxide, sodium hydroxide, sodium propoxide, potassium hydroxide, potassium ethoxide, magnesium hydroxide, calcium hydroxide, or barium hydroxide), these salts are readily available. Other alkali salts of compounds of the present disclosure include, but are not limited to, copper (I), copper (II), iron (II), iron (III), manganese (II), and zinc salts. Compounds of the present disclosure contain one or more basic groups, such as groups that can be protonated, which can exist in the form of salts and can be used according to the disclosure in the form of addition salts thereof with inorganic or organic acids. Examples of suitable acids include hydrogen chloride, hydrogen bromide, hydrogen iodide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalene disulfonic acid, sulfoacetic acid, trifluoroacetic acid, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, carbonic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, malonic acid, maleic acid, malic acid, pamoic acid, mandelic acid, sulfamic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, taurocholic acid, glutaric acid, stearic acid, glutamic acid, or aspartic acid, as well as others known to those skilled in the art. The salt formed is especially hydrochloride, chloride, hydrobromide, bromide, iodide, sulfate, phosphate, methanesulfonate (mesylate), toluenesulfonate, carbonate, bicarbonate, formates, acetate, sulfoacetate, trifluoromethanesulfonate, oxalate, malonate, maleate, succinate, tartrate, malate, pamoate, mandelate, fumarate, lactate, citrate, glutarate, stearate, aspartate and glutamate. In addition, the stoichiometry of the salt formed by the compounds of the present disclosure can be an integer multiple or a non-integer multiple of 1.

[0086] Compounds of the present disclosure containing basic nitrogen-containing groups can be treated with reagents such as C 1-4 Quaternization of alkyl halides, for example, methyl, ethyl, isopropyl and tert-butyl chloride, bromine and iodine; di-C 1-4Alkyl sulfates, such as dimethyl sulfate, diethyl sulfate, and dipentyl sulfate; C 10-18 Alkyl halides, such as decyl, dodecyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides; and aryl C 1-4 Alkyl halides, such as benzyl chloride and phenethyl bromide.

[0087] If the compounds of the present disclosure contain both acidic and basic groups in the molecule, the disclosure also includes, in addition to the above-mentioned salt forms, inner salts or betaines (zwitterions). The corresponding salts can be obtained by conventional methods known to those skilled in the art, for example, by contacting them with organic or inorganic acids or bases in a solvent or dispersant, or by anion exchange or cation exchange with other salts. The disclosure also includes all salts of the compounds of the present disclosure, which are not directly suitable for pharmaceutical use due to low physiological compatibility, but can be used, for example, as intermediates in chemical reactions or for the preparation of pharmaceutically acceptable salts. For a review of more suitable salts, see Stahl and Wermuth, Handbook of Pharmaceutical Salts: Properties, Selection and Use (Wiley-VCH, 2002).

[0088] The compounds of formula (I) and their pharmaceutically acceptable salts may exist in unsolvated and solvated forms. As used herein, the term "solvate" refers to a molecular complex comprising a stereoisomer, deuterated derivative, or stereoisomeric deuterated derivative of a compound of formula (I) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable solvent molecules. For example, the term "hydrate" is used when the solvent is water.

[0089] Formula (I) compound can have one or more chiral (asymmetric) centers. The present disclosure encompasses all stereoisomeric forms of formula (I) compound. The asymmetric center present in the formula (I) compound can have (R) or (S) configuration independently of one another. When the bond of the chiral carbon is described as a straight line in the structural formula of the present disclosure, or when the compound name is described in the case of the (R) or (S) chiral name without the chiral carbon, it should be understood that the (R) and (S) configuration of each such chiral carbon and therefore each enantiomer or diastereomer and mixture thereof are all included in the formula or name. The generation of a specific stereoisomer or its mixture can be identified in the example of obtaining such stereoisomer or mixture, but this in no way limits all stereoisomers and mixtures thereof to be included in the scope of the present disclosure. When the bond of a chiral carbon is depicted as a triangular solid line or a dashed line in the structural formula of the present disclosure, or when the compound name is depicted with the (R) or (S) chiral designation of the chiral carbon, it should be understood that the compound represented by the structural formula or name has a definite stereo configuration at the chiral carbon position and is to be distinguished from other stereoisomers, enantiomers, diastereomers, or mixtures thereof.

[0090] The present disclosure includes all possible enantiomers and diastereomers and mixtures of two or more stereoisomers, for example, mixtures of enantiomers and / or diastereomers of all ratios. Therefore, enantiomers are enantiomerically pure forms (as left-handed and right-handed enantiomers), racemic forms and two enantiomers of the disclosed subject matter in the form of mixtures of all ratios. In the case of cis / trans isomers, the present disclosure includes mixtures of all ratios of cis-form and trans-form and these forms. If necessary, single stereoisomers can be prepared by conventional methods (for example, by chromatography or crystallization, by using stereochemically uniform synthesis starting materials or by stereoselective synthesis). Optionally, derivatization can be carried out before stereoisomer separation. The separation of stereoisomer mixtures can be carried out in an intermediate step during the synthesis of compound of formula (I), or can be carried out on final racemic product. Absolute stereochemistry can be determined by X-ray crystallography of crystalline products or crystalline intermediates which have been derivatized, if necessary, with reagents containing stereocenters of known configuration. Alternatively, absolute stereochemistry can be determined by vibrational circular dichroism (VCD) spectroscopy.

[0091] Unless otherwise stated, structures depicted herein are also intended to include compounds that differ only in the presence of one or more isotopically enriched atoms, that is, compounds in which one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number prevalent in nature. Such compounds are termed "isotopic variants." The present disclosure is intended to include all pharmaceutically acceptable isotopic variants of the compounds of Formula (I). Examples of suitable isotopes for inclusion in the compounds of the present disclosure include, but are not limited to, isotopes of hydrogen, such as 2 H (i.e., D, deuterium) and 3 H (i.e. tritium); carbon, e.g. 11 C. 13 C and 14 C; chlorine, e.g. 36 Cl; fluorine, e.g. 18 F; iodine, e.g. 123 I and 125 I; nitrogen, e.g. 13 N and 15 N; oxygen, e.g. 15 O. 17 O and 18 O; phosphorus, e.g. 32 P; and sulfur, e.g. 35 Certain isotopic variants of the compounds of formula (I), for example those incorporating radioactive isotopes, are useful in drug and / or substrate tissue distribution studies. In particular, those having isotopic variations which occur only after substitution with heavier isotopes, for example with deuterium (2 H or D) replaces hydrogen) in the depicted structure of different compounds may provide certain therapeutic advantages, for example, due to greater metabolic stability, increased in vivo half-life or reduced dosage requirements, and therefore may be used in some specific situations. Isotopic variations of the compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by methods analogous to those described in the accompanying examples and by using appropriate isotopically labeled reagents instead of the non-labeled reagents previously employed.

[0092] When describing the structures of compounds herein, the undesignated hydrogen atoms in the shown formula are D (i.e., 2 H), it is generally understood that the hydrogen at this position is a hydrogen isotope " 1 hydrogen( 1 H)" or in a form with natural isotopic abundance in its natural state. The structures shown indicate that the hydrogen atoms are D (i.e., 2 H, deuterium), it should be understood that the hydrogen at this position is a hydrogen isotope " 2 hydrogen( 2 H, D, deuterium)" or in a form in which deuterium is present at a greater isotopic abundance than natural deuterium (e.g., a deuterium abundance of greater than 50%, greater than 60%, greater than 70%, greater than 80%, greater than 90%, greater than 95%, greater than 96%, greater than 97%, greater than 98%, greater than 99%, greater than 99.5%, or 100%).

[0093] Pharmaceutically acceptable solvates according to the present disclosure may include those wherein the solvent of crystallization may be isotopically substituted, for example D2O, d6-acetone, d6-DMSO.

[0094] One way to implement the present disclosure is to administer the compound of formula (I) in the form of a prodrug. Therefore, certain derivatives of the compound of formula (I) may themselves have little or no pharmacological activity, and when administered to the body or on the body, they are converted into a compound of formula (I) with the desired activity, for example, by hydrolytic cleavage, particularly by hydrolytic cleavage promoted by esterases or peptidases. Such derivatives are referred to as "prodrugs." More information on the use of prodrugs can be found in, for example, T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems", Vol. 14, ACS Symposium Series, and E. B. Roche (Ed.), "Bioreversible Carriers in Drug Design", Pergamon Press, 1987, American Pharmaceutical Association. Reference can also be made to Nature Reviews / Drug Discovery, 2008, 7, 355, and Current Opinion in Drug Discovery and Development, 2007, 10, 550.

[0095] Prodrugs according to the present disclosure can be prepared, for example, by replacing appropriate functional groups present in compounds of formula (I) with certain moieties known to those skilled in the art, for example, the "promoieties" described in H. Bundgaard, "Design of Prodrugs", Elsevier, 1985, and YM Choi-Sledeski and CG Wermuth, "Designing Prodrugs and Bioprecursors", Practice of Medicinal Chemistry, 4th edition, Chapter 28, 657-696, Elsevier, 2015. Thus, prodrugs according to the present disclosure can include, but are not limited to, (a) ester or amide derivatives of carboxylic acids in compounds of formula (I), if any; (b) amide, imine, carbamate, or amine derivatives of amino groups in compounds of formula (I); (c) oxime or imine derivatives of carbonyl groups in compounds of formula (I), if any; or (d) methyl, primary alcohol, or aldehyde groups in compounds of formula (I), if any, that can be metabolically oxidized to carboxylic acids.

[0096] References to compounds of formula (I) include the compounds themselves and prodrugs thereof. The present disclosure includes such compounds of formula (I) as well as pharmaceutically acceptable salts of such compounds and pharmaceutically acceptable solvates of said compounds and salts.

[0097] Use and application

[0098] The compounds of the present disclosure (stereoisomers, deuterated derivatives, or stereoisomeric deuterated derivatives of compounds of Formula (I))—or pharmaceutically acceptable salts, solvates, and mixtures thereof in all ratios—are useful as pharmaceuticals. They have been found to exhibit pharmacological activity that inhibits PLK1. It is hypothesized that, through this activity, the compounds of the present disclosure may prevent or reverse dysregulated PLK1 activity. By preventing dysregulated PLK1 activity, they may be able to exert their role as tumor suppressors. In addition to preventing or reversing dysregulated PLK1 activity, the pharmacological activity of the compounds of the present disclosure may also be used in other pathophysiological conditions where inhibition of PLK1 would be beneficial.

[0099] Therefore, the compounds of the present disclosure, as PLK1 inhibitors, are particularly useful for treating diseases and conditions resulting from dysregulated PLK1 activity and / or diseases and conditions associated with PLK1, such as cancer, including, but not limited to, cancers such as leukemia, lymphoma, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, colorectal cancer, liver cancer, gastric cancer, esophageal cancer, melanoma, multiple myeloma, and sepsis, etc. Without wishing to be bound by any particular theory or explanation, it is hypothesized that these compounds may be able to achieve this goal by acting directly on cancer cells and / or indirectly by modulating the immune system's response to tumors.

[0100] The compounds of the present disclosure can be administered in an amount effective to treat the diseases or conditions described herein. The compounds of the present disclosure can be administered as the compounds themselves, or alternatively, as pharmaceutically acceptable salts. For the purpose of administration and dosing, the compounds of the present disclosure themselves (stereoisomers, deuterated derivatives, or stereoisomeric deuterated derivatives of compounds of formula (I)) or their pharmaceutically acceptable salts, solvates will be referred to simply as compounds of the present disclosure.

[0101] The compounds of the present disclosure are administered by any suitable route in the form of pharmaceutical compositions suitable for such route and in a dose effective for the intended treatment.The compounds of the present disclosure can be administered orally, rectally, vaginally, parenterally or topically.

[0102] As used herein, the term "administer" refers to absorbing, ingesting, injecting, inhaling, implanting or otherwise introducing a compound of the present disclosure or its pharmaceutical composition. The term "treating" refers to reversing, alleviating, delaying the onset of "pathological conditions" (e.g., diseases, disorders or conditions, or one or more signs or symptoms thereof) as described herein or inhibiting their progression. In certain embodiments, treatment may be administered after one or more signs or symptoms of the disease or condition have developed or have been observed. In other embodiments, treatment may be performed in the absence of signs or symptoms of the disease or condition. For example, susceptible individuals may be treated before the onset of symptoms (e.g., according to a history of symptoms and / or according to genetic or other susceptibility factors). Treatment may also be continued after the symptoms subside, for example, to delay or prevent recurrence. As used herein, the terms "disease," "disorder," "condition," and "pathological condition" are used interchangeably.

[0103] Those skilled in the art can determine the dosage level of administration by routine experiments. The dosage regimen of the compound of the present disclosure and / or the composition comprising the compound is based on a variety of factors, including the type, age, weight, sex and medical condition of the patient; the severity of the condition; the route of administration; and the activity of the specific compound used. Therefore, the dosage regimen can be very different. For example, the dosage level of the compound of the present disclosure can be about 0.001 to about 100 mg / kg (i.e., mg / kg body weight) per day. In certain embodiments, the total daily dose of the compound of the present disclosure administered in a single or divided dose can be about 0.001 to about 10 mg / kg. It is not uncommon for the administration of the compound of the present disclosure to be repeated multiple times in one day.

[0104] Pharmaceutical composition

[0105] In some aspects, the present disclosure relates to pharmaceutical compositions comprising a stereoisomer, deuterated derivative, or stereoisomeric deuterated derivative of a compound of formula (I) as provided herein, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable carrier or excipient.

[0106] As used herein, the term "pharmaceutically acceptable carrier or excipient" refers to a carrier or excipient that can be used to prepare a pharmaceutical composition, which is generally safe, non-toxic, and not biologically or otherwise undesirable, and includes carriers or excipients that are acceptable for veterinary use as well as human pharmaceutical use. As used herein, a pharmaceutically acceptable carrier or excipient includes one or more such carriers or excipients. The specific carrier or excipient used will depend on the manner and purpose of the application of the compound of the present disclosure. Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, for example, Ansel, Howard C, et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro, Alfonso R., et al., Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005. One or more of buffers, stabilizers, surfactants, wetting agents, lubricants, emulsifiers, suspending agents, preservatives, antioxidants, opacifiers, glidants, processing aids, colorants, sweeteners, flavorings, flavorings, diluents and other known additives may also be included to provide a refined presentation of the drug (i.e., the compound or pharmaceutical composition provided herein) or to aid in the production of a pharmaceutical product (i.e., the drug).

[0107] The compositions of the present disclosure can be formulated into a variety of forms. These include, for example, liquid, semisolid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes, suppositories, etc. The form depends on the intended mode of administration and therapeutic application.

[0108] The pharmaceutical compositions of the present disclosure can be prepared by any well-known pharmaceutical techniques (e.g., effective formulations and administration procedures). The above considerations on effective formulations and administration procedures are well known in the art and are described in standard textbooks. For example, in Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania, 1975; Liberman et al., eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Kibbe et al., eds., Handbook of Pharmaceutical Excipients, 3rd edition, American Pharmaceutical Association, Washington, 1999, the formulation of drug products is discussed.

[0109] In yet another aspect, the present disclosure relates to a kit for treating diseases and conditions caused by dysregulated PLK1 activity and / or diseases and conditions associated with PLK1, comprising a stereoisomer, deuterated derivative, or stereoisomeric deuterated derivative of a compound of formula (I) as provided herein, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising a stereoisomer, deuterated derivative, or stereoisomeric deuterated derivative of a compound of formula (I) as provided herein, or a pharmaceutically acceptable salt or solvate thereof, a container, and optionally a package insert or label indicating treatment.

[0110] Treatment

[0111] In another aspect, the present disclosure relates to a method for treating diseases and conditions caused by dysregulated PLK1 activity and / or diseases and conditions associated with PLK1 in a subject in need thereof, which comprises administering to the subject a therapeutically effective amount of a stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of a compound of formula (I) as provided herein, or a pharmaceutically acceptable salt or solvate thereof, due to the PLK1 inhibitory activity of the compounds of the present disclosure.

[0112] As used herein, the term "subject in need thereof" refers to a subject who suffers from a disease or condition resulting from dysregulated PLK1 activity and / or a disease or condition associated with PLK1, or who is at increased risk of developing a PLK1-associated disease or condition relative to the general population. In certain embodiments, the subject is a warm-blooded animal. In certain embodiments, the warm-blooded animal is a mammal. In certain embodiments, the warm-blooded animal is a human.

[0113] As used herein, the term "diseases and conditions resulting from dysregulated PLK1 activity and / or diseases and conditions associated with PLK1" refers to any pathophysiological condition in which inhibition of PLK1 would be beneficial. In certain embodiments, the disease and condition resulting from dysregulated PLK1 activity and / or diseases and conditions associated with PLK1 is cancer. In certain embodiments, the disease and condition resulting from dysregulated PLK1 activity and / or diseases and conditions associated with PLK1 is a disease and condition selected from the group consisting of leukemia, lymphoma, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, colorectal cancer, liver cancer, gastric cancer, esophageal cancer, melanoma, multiple myeloma, and sepsis.

[0114] In another aspect, the present disclosure relates to stereoisomers, deuterated derivatives or stereoisomeric deuterated derivatives of compounds of formula (I) as provided herein, or pharmaceutically acceptable salts or solvates thereof for use in treating diseases and conditions caused by dysregulation of PLK1 activity and / or diseases and conditions associated with PLK1.

[0115] In another aspect, the present disclosure relates to the use of stereoisomers, deuterated derivatives or stereoisomeric deuterated derivatives of the compound of formula (I) as provided herein, or pharmaceutically acceptable salts or solvates thereof, in the preparation of medicaments for treating diseases and conditions caused by dysregulation of PLK1 activity and / or diseases and conditions associated with PLK1.

[0116] synthesis

[0117] The compounds of the present disclosure can be prepared by the general and specific methods described below using the common knowledge of those skilled in the art of synthetic organic chemistry. Such common knowledge can be found in standard reference books, for example, Barton and Ollis (eds.), Comprehensive Organic Chemistry, Elsevier; Richard Larock, Comprehensive Organic Transformations: A Guide to Functional Group Preparation, John Wiley and Sons; and Compendium of Organic Synthesis, Volumes I-XII, Wiley-Interscience.

[0118] The scheme described below is intended to provide a general description of the method for preparing the compounds of the present disclosure. Some compounds of the present disclosure may contain single or multiple chiral centers with stereochemical designations (R) or (S). It will be apparent to those skilled in the art that all synthetic transformations can be carried out in a similar manner, regardless of whether the material is enantiomerically enriched or racemic. In addition, the resolution of the desired optically active material can be carried out at any desired point in the procedure using known methods, such as those described herein and in the chemical literature.

[0119] Example

[0120] To describe the present disclosure in more detail, the following examples are presented. The examples described herein are intended to illustrate the compounds, methods, and compositions provided herein and should not be construed in any way as limiting their scope.

[0121] During the synthesis process, it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules involved. This can be achieved by conventional protecting groups, such as those described in TW Greene and PGM Wutts, Protective Groups in Organic Synthesis, 4th Edition, John Wiley and Sons. The protecting groups are optionally removed at a convenient subsequent stage using methods well known in the art.

[0122] The compounds of the present disclosure can be easily prepared according to the following reaction schemes and examples or modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, variants known to those skilled in the art but not mentioned in more detail may also be used. In addition, according to the reaction schemes and examples described herein, other methods for preparing the compounds of the present disclosure will be apparent to those skilled in the art. Unless otherwise indicated, all variables are as defined above. In general, in chemical procedures, all reagents and starting materials can be purchased from commercial suppliers or can be easily prepared by those skilled in the art.

[0123] Exemplary compounds are shown in Table 1.

[0124] Table 1

[0125] Preparation of intermediates

[0126] Step 1, Synthesis of Compound 2

[0127] At room temperature, compound 1 (40.0 g, 408.2 mmol, 1.0 eq) was dissolved in EtOH (40 mL), and p-toluenesulfonic acid (PTSA) (7.0 g, 40.8 mmol, 0.1 eq) was added, and the mixture was stirred and refluxed overnight. After TLC showed no residual compound 1, the mixture was concentrated. The residue was dissolved in EtOAc (200 mL), washed with saturated sodium bicarbonate solution (100 mL × 3) and anhydrous Na2SO4, and concentrated to give a crude product. The residue was purified by silica gel column chromatography (petroleum ether / EtOAc = 100:1) to give compound 2 (30.0 g, 60.1%) as a yellow oil. 1HNMR (300MHz, DMSO-d6): δppm 5.98 (t, J = 4.5Hz, 1H), 3.67 (q, J = 6.9Hz, 2H), 2.46-2.24 (m, 4H), 1.95-1.77 (m, 2H), 1.22 (t, J = 6.9Hz, 3H). LCMS:141.1([M+H] + ).

[0128] Step 2, Synthesis of Compound 4

[0129] Compound 2 (20.0 g, 142.7 mmol, 1.0 eq) was dissolved in THF (250 mL) under nitrogen. LiHMDS (171 mL, 171.2 mmol, 1.2 eq, 1 M in THF) was added dropwise at -50°C. Stirring was continued at this temperature for 30 minutes. Compound 3 (22.2 mL, 157.0 mmol, 1.1 eq) was added dropwise at -50°C. The mixture was returned to room temperature and stirred overnight. After LC-MS showed the complete disappearance of compound 2, the pH was adjusted to 4 with 1N HCl (approximately 180 mL) under ice-water bath. The mixture was extracted with ethyl acetate three times, 300 mL each time. The organic phases were combined and dried over anhydrous sodium sulfate. The solvent was removed by rotary evaporation to obtain a residue, which was further purified by column chromatography to afford compound 4 (20.0 g, 58.3%) as a yellow oil. 1 H NMR (300MHz, CDCl3): δppm 14.93(s,1H),5.88(d,J=4.8Hz,1H),4.34(q,J=6.9Hz,2H),3.82(q,J=6. 9Hz, 2H), 2.89 (t, J = 6.9Hz, 2H), 2.40 (q, J = 5.1Hz, 2H), 1.50-1.32 (m, 6H).

[0130] Step 3, Synthesis of Compound 5

[0131] Compound 4 (20.0 g, 83.3 mmol, 1.0 eq) was dissolved in acetic acid (200 mL), and 2-hydroxyethylhydrazine (6.3 g, 83.3 mmol, 1.0 eq) was added under stirring at room temperature. Stirring was continued at room temperature for 2 hours until compound 4 completely disappeared as monitored by LCMS. The reaction solution was concentrated, and the residue was dissolved in 500 mL of ethyl acetate, washed with water, saturated sodium bicarbonate 3 times, and saturated brine 3 times. After drying over anhydrous sodium sulfate, the desiccant was filtered off, and the solvent was removed by rotary evaporation to obtain a light yellow compound 5 (16.0 g, 76.2%). 1H NMR (300MHz, DMSO-d6): δppm 4.86(t,J=5.7Hz,1H),4.54(t,J=5.7Hz,2H),4.29(q,J=6.9Hz,2H),3.72(q,J=5.7Hz,2 H), 2.93 (t, J = 6.0Hz, 2H), 2.62-2.42 (m, 2H), 2.13-1.95 (m, 2H), 1.30 (t, J = 7.2Hz, 3H). LCMS:253.1([M+H] + ).

[0132] Step 4, Synthesis of Intermediate Int-A

[0133] Compound 5 (20.0 g, 79.3 mmol, 1.0 eq) was dissolved in DMF (180 mL) and compound 6 (48.3 g, 237.9 mmol, 3.0 eq) was added. The mixture was stirred at 60°C for 2 hours. After LCMS monitoring showed that compound 5 had completely disappeared, the mixture was cooled to room temperature, the reaction solution was poured into 1000 mL of water, and extracted with ethyl acetate six times. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, the desiccant was filtered off, and the solvent was removed by rotary evaporation to obtain a light yellow intermediate Int-A (13.0 g, 66.7%) without further purification. 1 H NMR (300MHz, DMSO-d6): δppm 7.48(s,1H),4.84(brs,1H),4.60(t,J=6.0Hz,2H),4.27(q,J=7.2Hz,2H),3.78-3.6 5(m,2H),3.11(s,6H),2.96-2.86(m,2H),2.86-2.76(m,2H),1.29(t,J=7.2Hz,3H).

[0134] Step 5, Synthesis of Intermediate A1

[0135] Intermediate Int-A (6.0 g, 0.7 mmol, 1.0 eq) was dissolved in DMF (60 mL), and compound 7 (4.7 g, 48.8 mmol, 2.5 eq) was added. The reaction was allowed to proceed at 110°C under N₂ protection for 12 hours. LCMS monitored the reaction until no INT-A residue remained. The mixture was cooled to room temperature and poured into 180 mL of water. Extraction was performed three times with ethyl acetate. The organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. The desiccant was filtered off, and the solvent was removed by rotary evaporation to obtain the crude product. Purification by column chromatography afforded the pale yellow intermediate (3.6 g, 60.8%). 1H NMR (400MHz, CDCl3): δppm 8.20(s,1H),5.10(s,2H),4.93(t,J=4.8Hz,2H),4.42(q,J=7.2Hz,2H),4.13(t,J =4.8Hz, 2H), 3.06 (t, J = 7.6Hz, 2H), 2.81 (t, J = 7.6Hz, 2H), 1.40 (t, J = 7.2Hz, 3H). LCMS:304.1([M+H] + ).

[0136] Step 6, Synthesis of Intermediate A2

[0137] Intermediate A1 (4.0 g, 13.2 mmol, 1.0 eq) was dissolved in DME (320 mL), and CsI (6.9 g, 26.4 mmol, 2.0 eq), I2 (3.3 g, 13.2 mmol, 1.0 eq), CuI (1.0 g, 5.3 mmol, 0.4 eq), and isoamyl nitrite (4.6 g, 39.6 mmol, 3.0 eq) were added. The reaction mixture was reacted at 80°C for 3 hours. After cooling to room temperature, a white solid precipitated. The solid was filtered and dissolved in 200 mL of dichloromethane. The solution was washed with aqueous ammonia, sodium thiosulfate solution, and saturated brine, and then dried over anhydrous sodium sulfate. The desiccant was filtered out, and the solvent was removed by rotary evaporation to obtain the crude product. The yellow intermediate A2 (2.0 g, 36.6%) was purified by column chromatography. 1 H NMR (400MHz, CDCl3): δppm 8.30(s,1H),4.92(t,J=4.8Hz,2H),4.42(q,J=7.2Hz,2H),4.14(t,J=4.8H z, 2H), 3.15 (t, J = 7.2Hz, 2H), 2.94 (t, J = 8.0Hz, 2H), 1.41 (t, J = 7.2Hz, 3H). LCMS:415.1([M+H] + ).

[0138] Synthesis of intermediate A4

[0139] HOBT (4.0 g, 29.6 mmol, 1.0 eq) was dissolved in methanol (40 mL), and aqueous ammonia (2.4 mL) was added and stirred at room temperature for 5 hours. A solid precipitated and was filtered to obtain a white solid, which was washed with petroleum ether and dried to obtain intermediate A4 (3.6 g, 79.9%).

[0140] Synthesis of intermediate A8

[0141] The first step is to synthesize A7 ((R)-tert-butyl hexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate-1,1,4,4-d4)

[0142] A6 (12 g, 77.4 mmol) was dissolved in a mixture of CD3OD (25 mL) and DCM (500 mL) and heated to reflux for 8 h. The solvent was removed by rotary evaporation, and the residue was redissolved in CD3OD (25 mL) and DCM (500 mL). The mixture was refluxed for 8 h, and the solvent was removed to afford a white solid. This solid was dissolved in THF (200 mL), and LiAlD4 (8.13 g, 193.5 mmol) was added at room temperature. The mixture was refluxed for 1 h, cooled to 0°C, and DCM (500 mL), water (8.13 mL), and 15% NaOH (8.13 mL) were added. (Boc)2O (33.75 g, 154.9 mmol) and TEA (23.46 g, 232.2 mmol) were added to the reaction solution, and the mixture was stirred at room temperature for 8 hours. The insoluble matter was filtered off, and the filtrate was concentrated and purified by silica gel column chromatography to obtain a brown oil A7 (12.7 g, 71%). LCMS: 231.2 [M+H] +

[0143] Step 2: Synthesize A8

[0144] The intermediate A7 was dissolved in MeOH (10 mL), and dioxane hydrogen chloride solution (4N, 10 mL) was added and reacted at room temperature for 16 hours. The solvent was removed and the crude product A8 (1.26 g) was obtained without further purification.

[0145] Synthesis Example 1. Synthesis of Compounds CPD02 and CPD03

[0146] Step 1, synthesis of compound 6

[0147] To a mixture of intermediate A3 (550.0 mg, 1.9 mmol, 1.0 eq), X-phos (190.7 mg, 0.4 mmol, 0.2 eq), (R)-octahydropyrrolo[1,2-A]pyrazine (718 mg, 5.7 mmol, 3 eq) and Cs2CO3 (1.2 g, 3.8 mmol, 2.0 eq) was added 1,4-dioxane (55 mL), and Pd2(dba)3 (183.1 mg, 0.2 mmol, 0.1 eq) was added at room temperature. The reaction system was replaced with N2 three times. The reaction mixture was heated to 90°C under N2 protection for 6 hours, cooled to room temperature, concentrated, and added with 15 mL of water. The mixture was extracted with dichloromethane three times. The organic phase was washed with saturated brine three times and dried over anhydrous sodium sulfate. The desiccant was filtered off and the solvent was evaporated off by rotary evaporation to obtain a crude product. The crude product was purified by column chromatography to obtain a light yellow solid compound 6 (370 mg, 58.1%). LCMS: 332.1 ([M+H] + ).

[0148] Step 2, synthesis of compound 7

[0149] Compound 6 (370.0 mg, 1.1 mmol, 1.0 eq) was dissolved in ethyl acetate (7.4 mL) and Pd / C (148.0 mg, 40% wt) was added. The mixture was reacted at room temperature under H2 overnight. The catalyst was filtered off and the mixture was concentrated to give a crude product of compound 7 (300 mg). The crude product was used directly in the subsequent reaction without purification. LCMS: 302.7 ([M+H] + ).

[0150] Step 3, synthesis of compound 8

[0151] In a glove box, DMF (2 mL) was added to a mixture of intermediate A2 (120.0 mg, 0.29 mmol, 1.0 eq), compound 7 (174.6 mg, 0.58 mmol, 2.0 eq), K2CO3 (120.1 mg, 0.87 mmol, 3.0 eq), BINAP (72.2 mg, 0.12 mmol, 0.4 eq), and Pd(OAc)2 (9.7 mg, 0.06 mmol, 0.2 eq). The mixture was reacted at 120°C under nitrogen for 4 hours. LCMS was used to monitor the complete reaction of intermediate A2. The reaction mixture was cooled to room temperature, and water (10 mL) was added. The mixture was extracted three times with EtOAc. The organic phase was washed three times with saturated brine and dried over anhydrous sodium sulfate. The desiccant was filtered off, and the solvent was removed by rotary evaporation to obtain the crude product. Purification by column chromatography afforded compound 8 (100 mg, 58.7%) as a brown oil. LCMS: 588.2 ([M+H] + ).

[0152] Step 4, synthesis of compound 9

[0153] Compound 8 (100 mg, 0.17 mmol, 1.0 eq) was dissolved in MeOH (1 mL), THF (1 mL), and H2O (1 mL). KOH (19.0 mg, 0.34 mmol, 2.0 eq) was added and stirred at room temperature for 2 hours. The reaction solution was concentrated, 5 mL of water was added to the residue, and the mixture was extracted with ethyl acetate three times. The aqueous phase was lyophilized to obtain a crude product of compound 9 (80 mg), which was gray. LCMS: 560.2 ([M-K+H+H] + , signal in the acid form).

[0154] Step 5: Synthesis of compound CPD02

[0155] Compound 9 (80 mg, 0.14 mmol, 1.0 eq) was dissolved in DMF (2 mL), and EDCI (80.2 mg, 0.42 mmol, 3.0 eq) and intermediate A4 (63.8 mg, 0.42 mmol, 3.0 eq) were added. The mixture was stirred at room temperature for 4 hours. After HPLC analysis, compound 9 was consumed. 10 mL of water was added, and the mixture was extracted three times with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate. The desiccant was filtered off, and the solvent was removed by rotary evaporation to obtain the crude product. The crude product was analyzed by preparative liquid chromatography (mobile phase: acetonitrile, 0.1% formic acid, water ranging from 5% to 35%), and lyophilized to afford CPD02 (10.0 mg, 10.5% yield over two steps) as a yellow solid. 1 H NMR (400MHz, DMSO-d6): δppm 8.85(s,1H),8.33(s,1H),7.43(s,1H),7.31-7.23(m,3H),6.80(dd,J=9.2,2.1H z,1H),4.62(t,J=5.2Hz,2H),3.76(d,J=9.6Hz,1H),3.70-3.58(m,3H),3.10-2. 90(m,4H),2.85-2.69(m,3H),2.42(t,J=10.4Hz,1H),2.21(td,J=11.2,3.2Hz,1 H),2.13-1.95(m,2H),1.90-1.76(m,1H),1.76-1.60(m,2H),1.45-1.27(m,1H). LCMS:559.1([M+H] + ).

[0156] The synthesis of compound CPD03 is similar to that of CPD02, and the structural spectrum is 1H NMR (300MHz, DMSO-d6): δppm8.86(brs,1H),8.34(s,1H),7.44(s,1H),7.29- 7.15(m,3H),6.80(dd,J=9.1,2.9Hz,1H),4.66-4.54(m,3H),3.80-3.70(m,1H ),3.68-3.54(m,3H),3.08-2.93(m,4H),2.83-2.69(m,3H),2.31-2.22(m,1H) ,2.22-2.14(m,1H),2.09-1.96(m,2H),1.86-1.64(m,3H),1.43-1.29(m,1H). LCMS: 559.3 ([M+H] + ).

[0157] Synthesis Example 2. Synthesis of Compound CPD04

[0158] The first step is to synthesize A10

[0159] 5-Bromo-2-trifluoromethoxyaniline A9 (10.0 g, 39.0 mmol) was dissolved in EtOH (30 mL) and added dropwise to a solution containing cyanamide (3.28 g, 78 mmol), EtOH (10 mL) and H2O (2 mL). A mixture of 37% HCl (6.5 mL) and EtOH (20 mL) was added dropwise to the mixture, and the mixture was refluxed for 5 days. The reaction solution was cooled to room temperature, concentrated and diluted with water; 1N NaOH was added until the reaction solution became alkaline, extracted several times with ethyl acetate, dried over sodium sulfate and concentrated to obtain A10 (3.2 g, 27%).

[0160] Step 2: Synthesis of Intermediate 10

[0161] A10 (29.3 g, 98.3 mmol, 1.2 eq) was dissolved in DMF (400 mL), and a DMF solution (200 mL) of the intermediate INT-A (24 g, 81.9 mmol, 1.0 eq) was added. The reaction mixture was reacted at 110°C for 16 hours, cooled to room temperature, poured into ice water, and the insoluble matter was filtered to obtain a white solid compound 10 (21.2 g, 50%). LCMS: 528.2, 530.2 ([M+H] + ).

[0162] Step 3: Synthesis of intermediate compound 11

[0163] Compound 10 (21.2 g, 40.1 mmol, 1.0 eq) was dissolved in THF (500 mL), and NH4Cl (6.44 g, 120 mmol, 3.0 eq) and LiHMDS (240 mmol, 6.0 eq) were added. The mixture was stirred at room temperature for 30 minutes. The solvent was removed by rotary evaporation, and the residue was washed with water and dried to obtain compound 11 (16.8 g, 81.8%) as a white solid. LCMS: 513.1, 515.1 ([M+H] + ).

[0164] Step 4: Synthesis of CPD04

[0165] To a mixture of compound 11 (2.0 g, 3.9 mmol, 1.0 eq), intermediate A8 (1.26 g, 6.25 mmol, 1.6 eq), Pd2(dba)3 (285 mg, 0.312 mmol, 0.08 eq), and Davephos (123 mg, 0.312 mmol, 0.08 eq) were added THF (100 mL) and LiHMDSLi (40 mL, 40 mmol). The mixture was reacted at 100°C for 2 hours, quenched by water, and extracted with EtOAc (50 mL x 3). The organic phases were combined and the solvent was removed by rotary evaporation. The residue was purified by silica gel column chromatography to yield the desired product, CPD04, as a white solid (1 g, 45.6%). LCMS: 563.3 [M+H] + . 1 H NMR(400MHz, Methanol-d4)δ8.30(s,1H),7.57(d,1H),7.26(dd,1H),6.85(dd,1H),4.79(t,2H),3.84(t,2H),3.69(d, 1H),3.47(dt,1H),3.23(d,1H),3.07(q,3H),2.88(t,2H),2.20(dt,1H),2.14-2.05(m,2H),1.97(s,1H),1.85(q,1H).

[0166] Synthesis Example 3. Synthesis of Compound CPD06

[0167] To a mixture of compound 11 (2.0 g, 3.9 mmol, 1.0 eq), N-methylpiperazine-2,2,3,3,5,5,6,6-D8 hydrochloride (1.13 g, 6.25 mmol, 1.6 eq), Pd2(dba)3 (285 mg, 0.312 mmol, 0.08 eq), and Davephos (123 mg, 0.312 mmol, 0.08 eq) were added THF (100 mL) and LiHMDS (40 mL, 40 mmol). The mixture was reacted at 100°C for 2 hours, quenched by water, and extracted with EtOAc (50 mL x 3). The organic phases were combined and the solvent removed by rotary evaporation. The residue was purified by silica gel column chromatography to yield the desired product, CPD06, as a white solid (1 g, 47.4%). LCMS: 541.3 [M+H] + , 1 H NMR(400MHz,DMSO-d6)δppm 8.92(s,1H),8.34(s,1H),7.45(bs,1H),7.27-7.21(m,3H),6.80(dd,1H) ,4.62(q,3H),3.62(q,2H),2.97(t,2H),2.79(t,2H),2.49-2.32(m,3H).

[0168] Experimental Example 1. Pharmacokinetic study in mice

[0169] The purpose of this study was to investigate the pharmacokinetic properties of the disclosed compounds following intravenous injection (IV) and oral administration (PO) in female CD1 mice. Plasma was collected at 0, 0.083, 0.25, 0.5, 1, 2, 4, 7, and 24 hours after administration. Plasma concentrations at different time points were determined by LC-MS / MS, and relevant pharmacokinetic parameters were calculated using WinNonlin software.

[0170] 1.1. Test materials

[0171] 1.1.1 The reagents and instruments used in this example are as follows:

[0172] Table 2. Reagent information

[0173] Table 3. Instrument information

[0174] 1.1.2 Experimental Animals:

[0175] Female CD1 mice were purchased from Spefox Laboratory Animal Technology Co., Ltd., aged 6-8 weeks and weighing 20-30 g. Female CD1 mice were housed in a controlled environment (set temperature at 20-25°C and relative humidity at 40-70%). A 12-hour light / 12-hour dark cycle was maintained unless interrupted for study-related events.

[0176] 1.2. Experimental procedures

[0177] 1.2.1 Preparation of experimental compound solution

[0178] The positive reference compound used in this example is NMS-P937, which has the structure shown in the following formula:

[0179] The compound solution is prepared in a clean bench and is ready for use. Mix thoroughly before use to ensure uniformity. Specific compound preparation methods are shown in the table below:

[0180] Preparation of 5 mg / mL stock solutions of compounds CPD02 and CPD03

[0181] Preparation of 20 mg / mL stock solutions of compounds CPD04, CPD06, and NMS-P937

[0182] 1.2.2 Administration:

[0183] Dosage: IV

[0184] Solvent ratio: 10% DMSO + 90% (20% SBE-β-CD)

[0185] Table 4. Doses used in IV administration

[0186] Dosage: PO

[0187] Solvent ratio: 10% DMSO + 90% (20% SBE-β-CD)

[0188] Table 5. Doses used in PO administration

[0189] Solvent ratio: 0.5% MC + 1% Tween-20

[0190] Table 6. Doses used in PO administration

[0191] 1.2.3 Drug administration and blood sample collection protocol

[0192] Animals were randomly divided into groups before the experiment. Mice were fasted for 12 hours before dosing and resumed free feeding 4 hours after dosing. The animal groups and blood collection schedules are shown in the table below.

[0193] Table 7. Animal grouping and blood collection time arrangement

[0194] All blood samples were transferred into plastic microcentrifuge tubes containing anticoagulant (EDTA-K2), then centrifuged at 4000 g for 5 min at 4°C. The supernatant was transferred into microcentrifuge tubes without anticoagulant, and the plasma was stored in a -75±15°C refrigerator until detection.

[0195] 1.3. Data and Results

[0196] The blood samples were purified by HPLC and analyzed by mass spectrometry to obtain the plasma concentration-time curve of the disclosed compound.

[0197] For compounds CPD02 and CPD03, HPLC instrument Waters ACQUITY was used, and the HPLC purification conditions are as follows:

[0198] Table 8. HPLC purification conditions

[0199] For compounds CPD04 and CPD06, HPLC instrument AB SHIMADZU LC-30AD was used, and the HPLC purification conditions are as follows:

[0200] Table 9. HPLC purification conditions

[0201] The pharmacokinetic parameters were estimated by non-compartmental model method (calculated by Phoenix WinNonlin software). IV pharmacokinetic parameters include CL, T 1 / 2 , C0, AUC, MRT, Vss; PO pharmacokinetic parameters include T 1 / 2 、T max 、C max , AUC, MRT, etc.

[0202] The calculation formula of bioavailability F is as follows:

[0203] The pharmacokinetic parameters of the disclosed compounds obtained in this example are summarized as follows:

[0204] Table 10. Pharmacokinetic parameters of intravenous injection in SD mice

[0205] Table 11. Pharmacokinetic parameters of SD mice after oral administration

[0206] Pharmacokinetic data indicate that the disclosed compounds have an appropriate half-life in mice. The oral bioavailability of the stereo-designed R-configuration molecule CPD02 is significantly higher than that of the S-configuration CPD03 and higher than that of NMS-P937. The bioavailability of the deuterated compounds is significantly higher than that of the non-deuterated molecules (CPD04 vs. CPD02, CPD06 vs. NMS-P937).

[0207] Test Example 2. Proliferation inhibitory activity on cell line PSN1

[0208] Test materials

[0209] The reagents and instruments used in this example are as follows:

[0210] Table 12 Cell line information

[0211] Table 13. Information on main reagents and consumables

[0212] Table 14. Instrument and software information

[0213] Table 15. Compound information and stock solution preparation

[0214] 2.2 Test methods

[0215] Day 0: Laying the boards

[0216] a) Adherent cells require digestion and centrifugation, while suspension cells can be directly centrifuged;

[0217] b) Resuspend in complete culture medium and count using an automated cell counter;

[0218] c) PSN1: Plate 6000 cells per well and dilute the cell suspension to the desired density;

[0219] d) 100 μL of cells were plated into each well and cultured in a 37°C, 5% CO2 incubator overnight to stabilize and balance the cells.

[0220] Day 1: Compound preparation and addition

[0221] a) The compound was prepared with DMSO to a solution with a final concentration of 200 times;

[0222] b) Dilute the compound 200-fold to 3-fold the final concentration using complete culture medium;

[0223] c) Add 50 μL of compound to each well, and add the same volume of culture medium to each well as a control. Incubate at 37°C with 5%

[0224] The cells were cultured in a CO2 incubator for 72 hours.

[0225] Day 4: Testing

[0226] a) Equilibrate the cell plate and CTG reagent to room temperature;

[0227] b) Add 30 μL to each well Reagents;

[0228] c) let it stand at room temperature for 15 minutes;

[0229] d) Detection by enzyme-labeled instrument.

[0230] Data Analysis

[0231] 1) Calculate IC using GraphPad Prism 8 50 ;

[0232] 2) %Inh=(1-(Raw data-Mean min ) / (Mean max -Mean min ))×100;

[0233] 3) Mean max positive control wells, containing only cells and an equal volume of culture medium;

[0234] 4) Mean min negative control wells, containing only culture medium;

[0235] 5) Raw data: Add the signal value of the compound well. If there are two replicate wells, it will be expressed as Raw1 and Raw2.

[0236] 2.3. Test results

[0237] The half-maximal inhibitory concentration IC of the disclosed compounds on the proliferation of PSN1 cells 50 See Table 16

[0238] Table 16 IC values ​​of the disclosed compounds on PSN1 cell proliferation 50

[0239] The results of the cell proliferation inhibition test indicate that the disclosed compounds have a significant growth inhibitory effect on a pancreatic cancer cell line (PSN1). The stereochemically designed R-configured molecule CPD02 is more sensitive than the S-configured CPD03. There is no significant difference in the biological activity (PSN1) between the deuterated compound and the non-deuterated molecule (CPD04 vs. CPD02, CPD06 vs. NMS-P937).

[0240] Experimental Example 3. Evaluation of metabolic stability of liver microsomes

[0241] 3.1. Test materials

[0242] The materials used in this embodiment are shown in Tables 17-19 below:

[0243] Table 17. Compound information

[0244] Table 18. Microsome information

[0245] Table 19. Reagent information

[0246] 3.2. Test methods

[0247] 3.2.1 Reagent preparation

[0248] 3.2.2 Experimental operation

[0249] 1) Prepare a 0.6289 mg / ml microsomal solution in PBS.

[0250] 2) Add 318 μL of 0.6289 mg / mL microsomal solution to each well of a 96-well incubation plate.

[0251] 3) Add 40 μL of 10 mM NADPH solution and 40 μL of 20 mM UDPGA solution to the incubation plate. For negative samples, add 80 μL of PBS (100 mM, pH = 7.4) solution. Vortex at 800 rpm for 10 seconds and pre-incubate in a 37°C water bath for 10 minutes.

[0252] 4) After pre-incubation, 2 μL of control drug or test compound was added to each well to initiate the reaction. The reaction was carried out in a 37°C water bath at 60 rpm.

[0253] 5) At 0.5, 15, 30, 45, and 60 minutes, remove 50 μL of the reaction system from each well and add it to 200 μL of cold methanol solution containing the internal standard to terminate the reaction.

[0254] 6) Mix well and centrifuge at 4°C, 4000 rpm for 30 minutes.

[0255] 7) Take 100 μL of supernatant and mix with 100 μL of ultrapure water for liquid chromatography-mass spectrometry analysis

[0256] *Internal standards: 50nM alprazolam, 50nM labetalol, and 100nM ketoprofen

[0257] 3.2.3 Data processing

[0258] The internal standard method is used, and the ratio of the sample peak area to the internal standard peak area is used to calculate the residual percentage (the ratio of the sample peak area to the internal standard peak area at 0.5 minutes is 100%).

[0259] The natural logarithm of the remaining percentage is plotted against the incubation time, and the slope of the line is the elimination rate constant k.

[0260] 3.3. Test results

[0261] The results of the evaluation of the metabolic stability of the disclosed compounds in liver microsomes are shown in Table 20.

[0262] Table 20. Summary of liver microsomal metabolic stability data

[0263] Conclusion: The in vitro clearance rate of the disclosed compounds is moderate

[0264] Test Example 4. Evaluation of the Permeability of Test Substances and Transporter Substrate Tests

[0265] 4.1. Test materials

[0266] 4.1.1 Compound Information

[0267] 4.1.2 Positive control drug information

[0268] 4.2. Test methods

[0269] 4.2.1 Caco-2 cell culture

[0270] a) Add 50 μL and 25 mL of cell culture medium to the upper and lower chambers of each well of a Transwell plate, respectively.

[0271] b) Before seeding the cells, pre-incubate the Transwell plate at 37°C, 5% CO2 for 1 hour;

[0272] c) The density is 2×10 550 μL of cell suspension of 10 cells / mL was seeded in the upper chamber and cultured in a cell culture incubator at 37°C, 5% CO2, and 95% relative humidity for 14-21 days, with the medium changed every two days;

[0273] d) Change the cell culture medium every other day for 7 days, and change it every day after 7 days;

[0274] e) The electrical resistance (TEER) of the monolayer was measured using EVOM3.

[0275] 4.2.2 ABBA testing process

[0276] a) Wash the transwell plate twice with prewarmed HBSS (10 mM HEPES, pH 7.4) and incubate at 37°C for 30 minutes.

[0277] b) Prepare a 1 mM DMSO stock solution of the test compound and dilute it 200-fold to 5 μM in buffer (pH 7.2-7.4);

[0278] c) Side A to B: Add 75 μL of 5 μM working solution to the upper chamber and 235 μL of HBSS (10 mM HEPES, pH 7.4) to the lower chamber;

[0279] d) B to A side: add 235 μL of 5 μM working solution to the lower chamber and 75 μL of HBSS (10 mM HEPES, pH 7.4) to the upper chamber;

[0280] e) Transfer 50 μL of the 5 μM working solution to a sample plate containing 200 μL of pre-chilled methanol internal standard as the zero point;

[0281] f) incubating at 37°C, 5% CO2, and 95% relative humidity for 2 hours;

[0282] g) After 2 hours of incubation, transfer 50 μL from each well to a sample plate containing 200 μL of methanol as an internal standard.

[0283] h) centrifuging the sample plate at 4000 rpm for 30 minutes;

[0284] i) Transfer 100 μL of supernatant to an assay plate containing 100 μL of water, centrifuge for 10 min, and perform LC-MS / MS analysis.

[0285] 4.2.3 Data Analysis

[0286] The apparent permeability coefficient (Papp, cm / s) and efflux ratio were calculated using Microsoft Excel.

[0287] V acceptor = 0.235 mL for A→B, and 0.075 mL for B→A

[0288] V donor = 0.075 mL for A→B, and 0.235 mL for B→A

[0289] Area = membrane surface area, cm 2 (0.143 for Corning 3391)

[0290] Time = total transit time, s

[0291] 4.3. Classification criteria

[0292] 4.4. Test results

[0293] The permeability results of the disclosed compounds in Caco-2 cells are shown in Table 21.

[0294] Table 21. Permeability results of Caco-2 cells

[0295] Test Example 5. Solubility Test Evaluation of Test Substances

[0296] 5.1. Test materials

[0297] 5.2. Test methods

[0298] 5.2.1 Buffer preparation

[0299] Weigh 7.098g of Na2HPO4 (Solution A) and dissolve it in 500mL of ultrapure water. Ultrasonicate. Weigh 3.40g of KH2PO4 (Solution B) and dissolve it in 250mL of ultrapure water. Slowly add Solution B dropwise to Solution A, adjusting the pH to 7.40±0.05.

[0300] 5.2.2 Test operation

[0301] a) Weigh approximately 1.0 mg of compound into three separate 1.5 mL glass vials (one vial for preparing the standard solution and the other two for testing solubility);

[0302] b) Add an appropriate volume (approximately 1000 μL) of assay buffer to each vial of solubility sample to a final concentration of 1 mg / mL;

[0303] c) placing a PTFE-encapsulated stainless steel stick stirrer into each vial, and then sealing the vials with PTDE / SIL silicone stoppers;

[0304] d) Transfer the solubility sample plate to a Thermomixer Comfort plate shaker and shake at 1100 rpm at 25°C for 24 hours.

[0305] e) After 24 hours, remove the stirring bar using a magnet;

[0306] f) Pipette 200 μL of sample into a filter plate, filter, and collect the filtrate;

[0307] g) 10 μL of the filtered sample and 10 μL of DMSO were added to 980 μL of methanol, and the mixture was further diluted 10-fold with methanol:water (1:1) to prepare the filtered sample for LC-MS / MS analysis;

[0308] h) For the standard sample, add DMSO to a final concentration of 1.0 mg / mL. Shake at 1100 rpm, 25°C for 5 minutes.

[0309] i) 10 μL of 1 mg / mL DMSO sample and 10 μL of buffer were added to 980 μL of methanol, and then diluted 10-fold with methanol:water (1:1) as a standard sample for LC-MS / MS analysis.

[0310] 5.2.3 Data processing

[0311] Solubility was calculated using Excel.

[0312] 5.3. Test results

[0313] The solubility results of the disclosed compounds are shown in Table 22

[0314] Table 22 Summary of thermodynamic solubility data

[0315] 5.4. Experimental conclusions

[0316] The compounds of the present disclosure have comparable solubility to NMS-P937.

[0317] Experimental Example 6. Pharmacodynamic study of compounds on colorectal cancer in mice

[0318] 6.1. Test materials

[0319] Balb / c nude mice, SPF grade, female, 6-8 weeks old, weighing 16-20 g, were purchased from Spefoc Biotechnology Co., Ltd. (Beijing)

[0320] HCT116 cells were purchased from ATCC;

[0321] The reagents and instruments used in the in vivo efficacy experiments are shown in Tables 23 and 24.

[0322] Table 23. Reagents used in in vivo efficacy experiments

[0323] Table 24. Instruments and equipment used in in vivo efficacy experiments

[0324] 6.2. Test methods

[0325] 6.2.1 Cell culture

[0326] HCT116 cells were cultured in RPMI-1640 medium containing inactivated 10% fetal bovine serum, 100 U / mL penicillin, 100 μg / mL streptomycin, and 2 mM glutamine in a 37°C, 5% CO2 incubator. After the cells were fully grown, they were divided into flasks and passaged. Tumor cells in the logarithmic growth phase were used for inoculation of tumors in vivo.

[0327] 6.2.2 Tumor Cell Inoculation and Grouping

[0328] The tumor cells were washed twice with PBS and the cell concentration was adjusted to 5 × 10 7 The resuspended tumor cells were inoculated into the right flank of the experimental animals, 100 μl / mouse, i.e. 5×10 6 / mouse. When the tumor grows to an average tumor volume of 100-150 mm 3 At 37 hr, animals were divided into 7 groups according to tumor volume and 8 animals were divided into each group. The specific dosing schedule is shown in Table 25. The first day of group dosing was designated as PG-D0.

[0329] Table 25. Dosage regimen

[0330] Note: The dosage volume is 10 μl / g. po: Oral administration. qd: Once daily for 10 consecutive days.

[0331] 6.2.3 Dose Adjustment or Suspension

[0332] During the administration period, pay attention to the health status of the animals. If any of the following conditions occur, the administration will be suspended:

[0333] 1) When the animal's body weight drops below 85% of the initial drug treatment weight, drug administration is stopped and continued until the animal's body weight recovers to 90% of the initial drug treatment weight;

[0334] 2) After administration, if the animal shows progressive slowness or abnormality in movement (such as hypothermia, difficulty breathing, diarrhea, arched back, convulsions, etc.), administration will be suspended until the animal's movement and general condition return to normal.

[0335] 6.2.4 Humane Endpoints for Experimental Animals

[0336] During the experiment, if any of the following situations occur, the animals should be euthanized using CO2:

[0337] 1) The animal exhibits abnormal movements or becomes paralyzed and is unable to eat or drink on its own;

[0338] 2) The animal's weight loss exceeds 20% of the weight at the start of drug treatment, and the veterinarian believes that it seriously affects the animal's welfare and / or the normal progress of the experiment.

[0339] 6.2.5 Euthanasia of experimental animals

[0340] At the end of the experiment or when a humane endpoint is achieved, animals are euthanized using CO2.

[0341] 6.2.6 Detection indicators

[0342] General Observation

[0343] After grouping until the end of the experiment, the animals were observed once a day. The observation contents included but were not limited to the tumor inoculation site, animal mental state, diet, exercise status, etc.

[0344] Weight Check

[0345] After grouping until the end of the experiment, the mice were weighed using an electronic balance every 3 days.

[0346] Tumor volume

[0347] After grouping until the end of the experiment, the long and short diameters of the mouse tumors were measured using an electronic vernier caliper every 3 days. The volume was calculated using the formula: volume (TV) = 0.5 × long diameter × short diameter 2 .

[0348] Tumor photography

[0349] At the end of the experiment, the mice were euthanized, the tumors were removed, and the removed tumors of the control group and the test group were neatly arranged and photographed.

[0350] 6.2.7 Drug Evaluation Indicators

[0351] Tumor growth inhibition rate (TGI) TV (%)

[0352] Tumor growth inhibition rate (%) = (1-T / C) × 100%

[0353] T / C = average RTV of treatment group / average RTV of control group

[0354] RTV is the relative tumor volume, which is the ratio of the tumor volume after drug administration to that before drug administration.

[0355] Tumor growth inhibition rate ≥ 30% and p < 0.05 after statistical analysis was considered effective.

[0356] Tumor weight inhibition rate TGITw (%)

[0357] Tumor weight inhibition rate (%) = (1-T / C) × 100%

[0358] T / C = average TW of the treatment group / average TW of the control group

[0359] TW is tumor weight

[0360] The tumor weight inhibition rate was ≥30% and p<0.05 after statistical analysis was considered effective.

[0361] 6.2.8 Statistical analysis

[0362] Graphpad Prism 8 statistical software was used to perform statistical analysis of tumor volume and tumor weight among the groups using the One-Way ANOVA test (homogeneity of variance). P < 0.05 was considered to be a significant difference.

[0363] 6.3. Test results

[0364] 6.3.1 Antitumor Effects of Test Drugs on HCT116 Subcutaneous Xenograft Mouse Model

[0365] As shown in Figure 2, mice were orally administered for 10 days. At the end of the experiment (PG-D22), compared with the vehicle group, the 60 mg / kg CPD04 administration group, as well as the 30 mg / kg and 60 mg / kg CPD06 and NMS-P937 administration groups, could significantly inhibit the growth of mouse tumors. The inhibition of tumors by each CPD04, CPD06 and NMS-P937 dosage group showed a dose-dependent effect. The tumor growth inhibition rate (TGI) of each group was 1.177, 1.164, and 1.157, respectively. TV ) See Table 26

[0366] Table 26. Tumor growth inhibition rate (TGI) of each group at the end of the experiment TV )

[0367] 6.3.2 Testing the safety of drugs in HCT116 subcutaneous xenograft mouse models

[0368] As shown in Figure 3, during the treatment period, three mice in the NMS-P937 60 mg / kg group died on PG-D12 and PG-D16, respectively. The weight of the mice in the NMS-P937 group fluctuated greatly. The weight loss may be due to the poor tolerance of tumor-bearing mice to NMS-P937. After drug withdrawal, the condition of some animals failed to improve in time and led to death. In contrast, the weight loss in other groups during the treatment period was less than 10%.

[0369] 6.4. Experimental conclusions

[0370] In summary, in the HCT116 subcutaneous transplanted tumor mouse model, each CPD04, CPD06 and NMS-P937 dose group inhibited the growth of mouse tumors in a dose-dependent manner. The CPD06 60mg / kg treatment group had a significantly better inhibitory effect on tumor growth than the other treatment groups. TV The efficacy reached 75.6%, and showed a significant toxicity advantage over the same dose of NMS-P937 (3 of 8 mice died in the same dose of NMS-P937 group).

[0371] Experimental Example 7. Pharmacodynamic Study of Compounds on Pancreatic Cancer in Mice

[0372] 7.1. Test materials

[0373] Pancreatic cancer cell line BxPC-3: purchased from ATCC. Other experimental materials and instruments are the same as those in Example 9.

[0374] 7.2. Test methods

[0375] The dosage regimen is shown in Table 27. The rest of the test methods are the same as those in Example 9.

[0376] Table 27. Dosage regimen

[0377] 7.3. Test results

[0378] 7.3.1 Antitumor Effects of Test Drugs on BxPC-3 Subcutaneous Transplanted Tumor Mouse Model

[0379] As shown in Figure 4, mice were orally administered with CPD06 for 10 days. At the end of the experiment, compared with the vehicle group, all the treatment groups were able to significantly inhibit the growth of mouse tumors ((p<0.0001)). Different doses of CPD06 showed a dose-dependent effect on the inhibition of pancreatic tumors. The tumor growth inhibition rate (TGI) of each group was 1.37 ± 1.13, and the tumor growth inhibition rate (TGI) of each group was 1.37 ± 1.13. TV ) See Table 28

[0380] Table 28. Tumor growth inhibition rate (TGI) of each group at the end of the experiment TV )

[0381] 7.3.2 Testing the safety of drugs in the BxPC-3 subcutaneous transplant mouse model

[0382] As shown in Figure 5, during the treatment period, two mice in the NMS-P937 60 mg / kg group died from PG-D9 and PG-D19, respectively. The weight of mice in the NMS-P937 60 mg / kg group fluctuated greatly. The weight loss may be due to the poor tolerance of tumor-bearing mice to NMS-P937. After drug withdrawal, the condition of some animals failed to improve in time and led to death. In contrast, the weight of other groups was relatively stable during the treatment period, with a decrease of less than 10%, and the weight recovered quickly after drug withdrawal.

[0383] 7.4. Test conclusions

[0384] In summary, in the BxPC-3 subcutaneous transplanted tumor mouse model, CPD06 inhibited tumor growth in a dose-dependent manner in each dose group. The CPD06 60mg / kg treatment group had a significantly better inhibitory effect on tumor growth than the other treatment groups. TV It reached 71%, showing that the efficacy was significantly better than that of the same dose of NMS-P937, and the toxicity was significantly better than that of the same dose of NMS-P937 group. No obvious toxic symptoms were found in CPD06 during the treatment period, but 2 of the 8 mice in the same dose of NMS-P937 group died.

[0385] Experimental Example 8. Pharmacodynamics study of the compound on pancreatic cancer in mice

[0386] 8.1. Test materials

[0387] M-NSG mice, SPF grade, female, 6-8 weeks old, weighing 16-20 g, were purchased from Shanghai Model Organisms Technology Co., Ltd.

[0388] PSN1 cells were purchased from ATCC;

[0389] The instruments used in the in vivo efficacy experiments are shown in Table 29.

[0390] Table 29. Reagents and instruments

[0391] 8.2. Test methods

[0392] 8.2.1 Drug preparation

[0393] 8.2.2 Cell culture

[0394] PSN1 cells were cultured in an incubator at 37°C and 5% CO2 in RPMI-1640 medium containing 10% inactivated fetal bovine serum. The cells were sub-plate-cultured every 2 to 3 days when they were confluent.

[0395] 8.2.3 Tumor Cell Inoculation and Grouping

[0396] 8.2.3.1 PSN1 cells in the logarithmic growth phase were collected and resuspended in PBS. The cell suspension was inoculated subcutaneously in the right flank of M-NSG mice using a 1 mL syringe (inoculated cell number: 5E6 / mouse + 30% M). The survival status of the mice and subcutaneous tumor formation were observed every other day.

[0397] 8.2.3.2 On the day of grouping, the mean tumor volume (~190 mm 3 ) and mouse body weight. The mice were randomly divided into 8 groups, 8 in each group;

[0398] 8.2.3.3 Initiate dosing according to the grouping scheme. All mice were administered by oral gavage at a volume of 10 mL / kg. The dose was administered once daily for a total of 6 doses. The mice's hair and condition were observed twice a week, and their body weight and tumor size were recorded. TGI% was calculated.

[0399] 8.2.3.4 Grouping of experimental animals

[0400] When the average tumor volume reached ∼190 mm 3 At the time of the study, mice with moderate tumor volumes were selected and randomly assigned to experimental groups based on tumor volume and weight, with 8 mice in each group. Dosing began one day after grouping. The specific dosing schedule is shown in the table below:

[0401] 8.2.4 Calculation formula

[0402] Tumor volume (TV)

[0403] TV=1 / 2×a×b2

[0404] Wherein: a represents the long diameter of the tumor; b represents the short diameter of the tumor.

[0405] Relative tumor volume (RTV)

[0406] RTV=V t / V initial ×100(%)

[0407] Among them, V initial When the drug is administered in groups (ie, d initial ) The tumor volume was measured, V t is the tumor volume at each measurement.

[0408] Relative tumor proliferation rate T / C (%)

[0409] T / C(%)=(T RTV / C RTV )×100%

[0410] Among them, TRTV represents the relative tumor volume of the treatment group, C RTV Relative tumor volume of the vehicle group is shown.

[0411] Tumor volume inhibition rate (TGI)

[0412] TGI=[1-(TV t -TV initial ) / (CV t -CV initial )]×100%

[0413] Among them, TV t represents the tumor volume of the treatment group at each measurement; TV initial represents the tumor volume of the treatment group at the time of drug administration; CV t represents the tumor volume of the control group at each measurement; CV initial It represents the tumor volume of the control group at the time of group administration.

[0414] 8.2.5 Animal Body Weight Change (BWC)

[0415] Weight change rate = (BW final -BW initial ) / BW initial ×100%

[0416] Among them, BW initial Indicates the body weight of animals when they were grouped and dosed; BW final Indicates the animal weight at each measurement.

[0417] 8.2.6 Data Analysis

[0418] The original data of measurement and observation must be recorded. The analysis and processing are based on the original data. The results are expressed as mean ± SEM. T-test is used to analyze the difference in tumor volume between the control group and the drug group. P < 0.05 indicates that there is a statistical difference.

[0419] 8.3. Test results

[0420] 8.3.1 Antitumor Effects of Test Drugs on PSN1 Subcutaneous Xenograft Mouse Model

[0421] As shown in Figure 6, mice were orally administered for 6 days. At the end of the experiment (day 31), compared with the vehicle group, all the treatment groups were able to significantly (p < 0.0001) inhibit the growth of mouse tumors. The NMS-P937 60 mg / kg group had a severe weight loss and half of the mice died, resulting in the inability to calculate the TGI. The tumor growth inhibition rate (TGI) of each group was 2.37 ± 0.13, which was 2.37 ± 0.17. TV ) See Table 30

[0422] Table 30. Tumor growth inhibition rate (TGI) of each group at the end of the experiment TV )

[0423] 8.3.2 Testing the Safety of Drugs in a PSN1 Subcutaneous Xenograft Mouse Model

[0424] As shown in Figure 7, during treatment, four mice in the NMS-P937 60 mg / kg group died on Days 27 and 31, respectively. At the endpoint, only two mice in the NMS-P937 60 mg / kg group had recovered slightly. This weight loss may be due to poor tolerance of NMS-P937 in tumor-bearing mice. No mice died in the CPD06 60 mg / kg group, and weight loss during dosing did not exceed 15%. Weight recovery occurred after drug withdrawal. No mice died in the CPD04 90 mg / kg group, and no weight loss was observed.

[0425] 8.4. Test conclusions

[0426] In summary, CPD06 60mg / kg and CPD04 90mg / kg can significantly inhibit the growth of tumors in PSN1 subcutaneous transplanted tumor mice. The CPD06 60mg / kg group had a significantly better inhibitory effect on tumor growth than the other treatment groups. TV Reaching 53%, the toxicity of NMS-P937 60 mg / kg in highly immunodeficient mice was much greater than that of CPD06 60 mg / kg and CPD04 90 mg / kg. 4 out of 8 mice died after being treated with NMS-P937 60 mg / kg.

[0427] The foregoing description is considered to be merely illustrative of the principles of the present disclosure. Furthermore, since many modifications and variations will be apparent to those skilled in the art, it is not desirable to limit the present disclosure to the exact configuration and process described above. Therefore, all suitable modifications and equivalents are considered to fall within the scope of the present disclosure as defined by the appended claims.

[0428] All publications, patents, and patent applications cited herein are hereby incorporated by reference into this disclosure in their entirety.

Claims

1. A stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of a compound of formula (I): or a pharmaceutically acceptable salt or solvate thereof, in, R 1 and R 2 are each independently selected from hydrogen, deuterium, deuterated or undeuterated C 1-6 Alkyl; or R 1 and R 2 Together with the N atom and the C atom to which it is attached, it forms an optionally substituted deuterated or undeuterated 5-membered heterocyclic ring; Optionally and / or Optionally substituted with one or more deuteriums.

2. A stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of the compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 Is deuterated or undeuterated C 1-6 Alkyl, preferably methyl or deuterated methyl, more preferably perdeuterated methyl; and / or R 2 It is hydrogen or deuterium.

3. A stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of the compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 and R 2 Together with the N atom and the C atom to which it is connected, it forms an optionally substituted 5-membered heterocyclic ring as described below: in, The 5-membered heterocyclic ring is optionally substituted with 1-7 deuterium.

4. A stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of the compound of formula (I) according to claim 3, or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 and R 2 Together with the N atom and the C atom to which it is connected, it forms an optionally substituted 5-membered heterocyclic ring selected from the following: in, The 5-membered heterocyclic ring is optionally substituted with 1-7 deuterium.

5. A stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of the compound (I) according to any one of the preceding items, or a pharmaceutically acceptable salt or solvate thereof, wherein Optionally substituted with 1-8 deuterium.

6. The stereoisomer, deuterated derivative or stereoisomer deuterated derivative of the compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein the stereoisomer, deuterated derivative or stereoisomer deuterated derivative of the compound of formula (I) is selected from the following:

7. A pharmaceutical composition comprising a stereoisomer, a deuterated derivative or a stereoisomeric deuterated derivative of a compound of formula (I) according to any one of claims 1 to 6, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or excipient.

8. A method for treating diseases and conditions caused by dysregulated PLK1 activity and / or diseases and conditions associated with PLK1 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a stereoisomer, deuterated derivative or stereoisomerically deuterated derivative of a compound of formula (I) according to any one of claims 1 to 6, or a pharmaceutically acceptable salt or solvate thereof.

9. The method according to claim 8, wherein the diseases and conditions caused by dysregulated PLK1 activity and / or diseases and conditions associated with PLK1 are selected from the group consisting of leukemia, lymphoma, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, colorectal cancer, liver cancer, gastric cancer, esophageal cancer, melanoma, multiple myeloma, and sepsis.

10. A stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of a compound of formula (I) according to any one of claims 1 to 6, or a pharmaceutically acceptable salt or solvate thereof for use in treating diseases and conditions caused by dysregulated PLK1 activity and / or diseases and conditions associated with PLK1.

11. A stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of a compound of formula (I) for use in treating diseases and conditions caused by dysregulated PLK1 activity and / or diseases and conditions associated with PLK1 according to claim 10, or a pharmaceutically acceptable salt or solvate thereof, wherein the diseases and conditions caused by dysregulated PLK1 activity and / or diseases and conditions associated with PLK1 are selected from the group consisting of leukemia, lymphoma, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, colorectal cancer, liver cancer, gastric cancer, esophageal cancer, melanoma, multiple myeloma, and sepsis.

12. [Corrected 04.02.2024 in accordance with Rule 26] Use of a stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of a compound of formula (I) according to any one of claims 1 to 6, or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for treating diseases and conditions caused by dysregulated PLK1 activity and / or diseases and conditions associated with PLK1.

13. The use according to claim 12, wherein the diseases and conditions caused by dysregulated PLK1 activity and / or the diseases and conditions associated with PLK1 are selected from the group consisting of leukemia, lymphoma, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, colorectal cancer, liver cancer, gastric cancer, esophageal cancer, melanoma, multiple myeloma, and sepsis.

14. A kit for treating diseases and conditions caused by dysregulated PLK1 activity and / or diseases and conditions associated with PLK1, the kit comprising A stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of a compound of formula (I) according to any one of claims 1 to 6, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition according to claim 7; Container; and Optional package insert or label indicating treatment.

15. The kit according to claim 14, wherein the diseases and conditions caused by dysregulated PLK1 activity and / or the diseases and conditions associated with PLK1 are selected from the group consisting of leukemia, lymphoma, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, colorectal cancer, liver cancer, gastric cancer, esophageal cancer, melanoma, multiple myeloma, and sepsis.